Chief Financial Officer
Prior to joining Impel NeuroPharma, John served as the Chief Financial Officer and Head of Corporate Development at Selecta Biosciences, a publicly traded biotechnology company focused on immune tolerance. Prior to this, he served as Head of Corporate Development at InfaCare Pharmaceutical Corp., a specialty pharmaceutical company, where he guided the acquisition of the company by Mallinckrodt plc. in 2017. Earlier, he was the Chief Financial Officer of Medgenics Inc., a publicly traded gene therapy company. He also previously held senior roles at Shire plc. and Devon Park Bioventures, a venture capital fund targeting investments in therapeutics companies. John brings to Impel extensive financing, licensing, merger and acquisition experience, and began his career serving a range of life sciences companies as an Associate Principal at McKinsey & Company. He received an M.D. from the Perelman School of Medicine at the University of Pennsylvania, an M.B.A. from the Wharton School at the University of Pennsylvania, a B.A. in psychology, philosophy and physiology from Oriel College, University of Oxford while completing a Rhodes Scholarship, and a B.S. in biology from Elizabethtown College.